All posts by : Felistas

Alcohol use disorder, which affects over 10% of Americans, can lead to persistent and serious insomnia. Difficulties falling asleep and staying asleep can last even after months of sobriety, increasing the risk of relapse. But treating withdrawal-related insomnia is difficult, partly because what’s going on in the brain in this condition remains largely mysterious.

A clinical trial comparing a one-page medication handout proposed by the U.S. Food and Drug Administration (FDA) with an updated version developed by researchers at the University of Pittsburgh that quantifies a drug’s risk and benefits showed that the latter was more informative and helped patients feel better equipped to make decisions.

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that patrols our body, ever vigilant for signs of infection or injury.

Testosterone worsens the damage caused by a heart attack by increasing the number of white blood cells released from the bone marrow. This is shown in a study by the University of Gothenburg, Sweden. The findings may have implications for the treatment of heart attacks in both men and women.

As Kansas deals with one of the largest tuberculosis outbreaks in the nation since the 1950s, Californians may be wondering whether they’re at risk.

This coastal valley made famous by the novelist John Steinbeck is sometimes known affectionately as “America’s salad bowl,” though the planting and harvesting is done mostly by immigrants from Mexico.

The U.S. Food and Drug Administration has approved Genentech’s Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

Heart disease is the leading cause of death in the U.S., according to the American Heart Association. Heart disease refers to a range of conditions, of which many can be prevented or treated by making healthy lifestyle choices.

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential for other cancers as well.

The U.S. Food and Drug Administration has approved Axsome Therapeutics’ Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.